A Study on the Efficacy and Safety of Dipheny-dimethyl-dicarboxylate in Patients with Chronic Liver disease.
- Author:
Hyoung Sik KIM
1
;
Soo Taek LEE
;
Dae Gon KIM
;
Deuk Soo AHN
Author Information
1. Department of Internal Medicine, Chonbuk National University, College of Medicine, Chonju, Korea.
- Publication Type:Original Article
- Keywords:
Chronic liver diseases;
dephenyl - dimethyl - dicarboxylate;
transaminase
- MeSH:
Alanine;
Aspartate Aminotransferases;
Hepatitis;
Humans;
Liver Diseases*;
Liver Failure;
Liver Function Tests;
Liver*;
Polyethylene Glycols;
Polysorbates;
Prognosis
- From:The Korean Journal of Hepatology
1996;2(1):54-60
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: The spectrum of clinical features of chronic liver disease bas wide range from asymptomatic cases to hepatic failure, The natural course and long-term prognosis of chronic liver disease also varies greately, and this diversity makes it diflicult to predict the clinical course of individual patient. The two majar approaches to the treatment of chronic liver disease are 1) directed toward the eradication of the virus and 2)designed to modulate cellular and humeral immunity. Progress has been made in the development of antiviral chernotherapeutic agents for hepatitis. But as yet no safe and reliably effective treatment or combination of treatrnents is available. In tkis study, we performed trial of diphenyl-dimethyl-dicarboxylate to evaluate the therapeutic effect and safety of it. METHODS: The ciinical trials of DDB(complex capsule of diphenyl dimethyl dicarboxylate 7.5mg and polysorbate 80 1,5mg and polyethylene glycol 6000 66mg) were carried out in 30 patients with chronic liver disease for 6 months. All patients had abnormal liver function test ouer a period of 6 months. RESULTS: In selected groups mean serum aspartate aminotransferase and alanine aminotrans- ferase dropped from pretreatment level of' 115.9+/-74.1 IU/L and 201.6+/-173.0 1U/L to posttreatment level of46.6+/-21.6 UU/L and 28.7+/-15.4IU/L, respectively(p<0.01). There was no significant hernatological and biochemical change after administration of DDB. Untoward side effects were easily controlled by discontinuing the drugs. CONCLUSIONS: Administration of DDB(for 6 months) appears to be effective for decrement of transaminase level and safe for the treatment of patients with chronic liver disease.
